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ABSTRACT 
Background: The endocrine pancreas contains multiple cell types co-localized 
into clusters called the Islets of Langerhans. The predominant cell types include 
alpha and beta cells, which produce glucagon and insulin, respectively. The 
regulated release of these hormones maintains whole body glucose 
homeostasis, essential for normal metabolism and to prevent diabetes and 
complications from the disease. Given the heterogeneous nature of islet 
composition and absence of unique surface markers, many previous studies 
have focused on the whole islet. Sorting islet cells by intracellular hormone 
expression overcomes this limitation and provides pure populations of individual 
islet cell subsets, specifically alpha and beta cells. This technique provides the 
framework for characterizing human islet composition and will work towards 
identifying the genetic changes alpha and beta cells undergo during 
development, growth, and proliferation.  
Methods: Human islets obtained from cadaveric donors are dissociated into a 
single cell suspension, fixed, permeabilized, and labeled with antibodies specific 
to glucagon, insulin, and somatostatin. Individual alpha, beta, and delta cell 
populations are simultaneously isolated using fluorescence activated cell sorting. 
Candidate gene expression and microRNA profiles have been obtained for alpha 
and beta cell populations using a quantitative nuclease protection assay. Thus 
vii 
far, RNA has been extracted from whole islets and beta cells and subjected to 
next generation sequencing analysis.  
Results: The ratio of beta to alpha cells significantly increases with donor age 
and trends higher in female donors; BMI does not appear to significantly alter the 
ratio. Further, we have begun to investigate the unique gene expression profiles 
of alpha and beta cells versus whole islets, and have characterized the 
microRNA profiles of the two cell subsets.  
Conclusions: By establishing methods to profile multiple characteristics of alpha 
and beta cells, we hope to determine how gene, miRNA, and protein expression 
patterns change under environmental conditions that lead to beta cell failure or 
promote beta cell development, growth, and proliferation.  
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PREFACE 
All experiments and data presented in this thesis are original in nature. They will 
serve as the springboard for future publications. All figures are also original, 
however, data analysis of next generation sequencing data and subsequent 
presentations of data were performed with Jia Xu of the Bioinformatics Core and 
are shown with her consent. 
We have performed many similar experiments on pancreatic islets isolated from 
nonhuman primates (NHP) in collaboration with Charles Roberts, Julie Carroll, 
and Kevin Grove at the Oregon Health & Science University. The benefit of these 
results is described in Chapter 5 as a future direction, however, the experimental 
data are not presented here.  
I have worked with Dale Greiner, Dean Brostowin, Susanne Pechhold, and Rita 
Bortell to extract transplanted human islets from mouse kidney. We eventually 
hope to isolate the transplanted islets and measure gene expression changes 
that might explain beta cell proliferation. Currently, our yield of extracted islets 
precludes completion of these experiments and the results have not been 
included in this thesis presentation. 
A detailed introduction precedes each experimental chapter. The Chapter 1 
introduction serves as an outline to focus on the scientific and clinical 
significance of these studies. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Pancreatic Islet Structure and Function 
The human pancreas is a gland that performs both endocrine and exocrine 
functions. The endocrine portion includes the Islets of Langerhans, which are a 
heterogeneous arrangement of alpha, beta, delta, PP, and epsilon cells that 
secrete hormones1,2. The pancreatic islets help to maintain total body glucose 
homeostasis through the regulated release of insulin and glucagon from beta and 
alpha cells, respectively. In response to food consumption and gastric emptying, 
blood glucose levels rise and insulin secretion from beta cells increases. 
Increased insulin secretion mediates glucose transporter type 4 (GLUT4) 
translocation to the surface of fat and muscle cells thereby increasing glucose 
uptake out of the bloodstream and into the cells where it is metabolized. In times 
of fasting, when there is little consumed glucose in the bloodstream, alpha cells 
respond by secreting glucagon. Glucagon release initiates glycogenolysis in the 
liver and adds additional sugar to the bloodstream. In addition to regulating blood 
glucose concentrations, insulin and glucagon concentrations are controlled by 
negative feedback. When insulin levels are high, this inhibits glucagon release 
and promotes glucose uptake. When glucagon levels are high, beta cell release 
of insulin is inhibited and glucose is produced by glycogenolysis or 
gluconeogenesis, in extended fasting. By working together, these two molecules 
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maintain a nearly constant blood glucose concentration to ensure that the body 
has enough energy without permitting dangerous fluctuations in blood glucose 
levels3. In patients with type 1 diabetes, glucose homeostasis is interrupted by a 
lack of endogenous insulin. In type 2 patients, increased insulin resistance or 
decreased insulin sensitivity result in the manifestation of the disease.  
Human Islet Transplant Successes and Limitations 
In order to combat the destruction of beta cells in a patient with type 1 diabetes, 
the first human islet transplant occurred in 1990. Its success at establishing 
insulin independence for over three weeks provided the proof of principle to 
pursue clinical trials4. The Edmonton Protocol followed up on this success by 
transplanting islets into diabetic patients without the need for glucocorticoid 
therapy over the course of two or three islet infusion from multiple donors5. 
These transplants were completed with a 67% success rate at establishing 
insulin independence for a median of 15 months post-transplant. Unfortunately, 
however, complete insulin independence in transplant patients hovered around 
10% after a five year post-transplant follow up6. A recent review in Diabetes Care 
(2012) analyzed 677 islet transplant cases that have occurred since 1999. This 
study showed that islet transplant success has improved markedly since the 
initial transplants took place. For islet donors who received this treatment 
between 2007-2010, approximately 44% maintained insulin independence for at 
least three years7. Overall, although islet transplants are not a true cure for type 
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1 diabetes, they have proven to increase C-peptide values, reduce hypoglycemic 
events, reduce average hemoglobin A1C values, and increase overall glucose 
stability7,8.  
As described, current attempts to cure diabetes by islet transplantation have had 
a lower than ideal success rate. In addition to a general shortage in 
transplantable islets, much of the inconsistency in islet transplant success is due 
to uneven donor islet quality. Chapter III will show how the demographics for islet 
donors are highly variable and uncontrolled. Donors are of different ages, have 
different body mass indexes (BMI), display varying ratios of beta to alpha cells, 
and isolated islets are cultured from organ donors who have experienced varying 
cold ischemia times, which can affect islet cell health and viability8,9. 
Furthermore, upon transplant, islets are still subject to the autoimmune attack 
that caused the initial case of diabetes, the standard alloimmune rejection, the 
lack of a native environment (given their infusion into the portal vein), and an 
overall absence of beta cell proliferation8. A gap exists in our knowledge and 
treatment between observing that islet transplants can remove insulin 
dependence and cure type 1 diabetes versus establishing a consistent method 
for successfully obtaining and maintaining to make it happen consistently. 
Research Focus on Islets and Beta Cells 
In an effort to prevent, treat, and cure both types of diabetes, research has 
focused on multiple aspects of diabetes pathophysiology. In type 1 diabetes, 
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researchers have investigated what initiates and perpetuates the autoimmune 
response that results in a process where autoreactive T cells destroy insulin 
producing beta cells, thereby causing diabetes. Studies have centered on the 
autoantigens, such as insulin or glutamic acid decarboxylase, that serve as 
targets for autoimmune response, regardless of whether they are specifically 
expressed in beta cells, islets, or simply within the endocrine system10,11. 
The focus on identifying the cause of type 1 diabetes, which also serves as a 
potential adversary to successful islet transplants, is also a key factor in efforts to 
generate new beta cells. Borowiak and Melton (2009) summarize the three 
potential avenues for programming beta cells and encouraging their proliferation 
and regeneration. This research is important in order to overcome the limitations 
discussed above that might restrict the success rate of human islet transplants in 
offering a sustainable, long-term, and permanent cure for type 1 diabetes. 
Current research focuses on generating beta cells de novo from embryonic cells 
or induced pluripotent stem cells. Since these stem cells can be programmed to 
potentially be any cell in the body, experiments have focused on replicating 
embryonic development by proceeding in an in vitro stepwise fashion using 
protein growth factors or small molecules to induce beta cell development12. 
Cells can also be induced to regain pluripotency and then reprogrammed to form 
beta cells. Fibroblasts, hepatocytes, and even alpha cells have been used in 
attempts to produce functional beta cells that will organize into islet cell 
clusters12,13. This strategy could be useful for avoiding alloimmune rejection 
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complications. Finally, given how current islet transplantation works and given 
the impaired beta cell function in type 2 diabetes, research is being performed to 
understand what transcriptional regulatory factors control the existence of beta 
cell progenitors that transiently exist during neonatal life, but apparently 
disappear following growth and development. If these genetic factors could be 
identified, understood, and induced to higher expression levels, it might be 
possible to induce beta cell proliferation and increase or sustain beta cell mass 
following transplantation or reduced beta cell function12.  
Throughout this thesis, our main goal is to be able to identify the genetic and 
regulatory components that control beta cell growth in response to environmental 
stimuli and demographic factors. We focus most of our efforts on using flow 
cytometry to obtain pure populations of islet cell subsets. Upon establishing 
these techniques, we have employed quantitative nuclease protection and next 
generation sequencing analyses. These methodologies will help us begin to 
establish the beta cell transcriptome and ways to detect changes in gene 
expression. By identifying which proteins are specifically expressed in the beta 
cell using these technologies, we aim to correlate changes in gene expression 
within the beta cell to observed increases in beta cell mass and proliferation.  
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CHAPTER II 
PANCREATIC ISLET SORTING INTO CELL SUBSETS 
Introduction 
Pancreatic islets are comprised of numerous cell types that perform specific 
endocrine functions. Alpha and beta cells work together in measuring blood 
glucose concentration and respond by releasing glucagon and insulin hormones, 
respectively, in order to maintain a human blood glucose level of 5 mM. Due to 
this heterogenous arrangement, an increased interest in determining the gene 
expression profiles of pancreatic islet cell subtypes at baseline and following 
manipulation has developed. A major limitation to pursuing these studies has 
centered on the difficulty in obtaining pure populations of alpha and beta cells 
that contain high quality RNA14. In order to direct gene expression studies to 
individual islet cell subsets, it is necessary to separate alpha, beta, and delta 
cells away from other material in the single cell suspensions. Flow cytometry 
serves as one method that has been used in multiple different ways to 
accomplish this goal. 
Researchers have taken advantage of the light scattering and autofluorescence 
measuring properties of flow cytometry analysis to separate the different cell 
types. Following hydrodynamic focusing of the cells into a single-file stream, the 
laser intercepts the cells causing light scatter. Forward scatter detectors measure 
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how much light in the laser path is blocked, which determines the size of the cell. 
Side scatter detectors measure how much light is scattered at a 90° angle from 
the laser path, which determines the density and granularity of the cell. The 
granular nature of insulin secretory vesicles results in a higher side scatter 
component in beta cells versus alpha and other islet cell types and allows for the 
enrichment of the beta cell population15,16.  
To further enhance the enrichment of beta cells, sorting protocols have 
capitalized on the high concentration of zinc that beta cells require for insulin 
secretion17. Newport Green is a non-toxic, zinc-specific dye that labels beta 
cells18. Through combination with a live-dead cell marker and a ductal cell-
specific antibody, the beta cell population can be further enriched19,20. This 
technique eliminates dead and ductal cells by creating gates that remove cells 
with probe-specific fluorescent properties. Cells that are Newport Green positive 
and have a high side scatter component are sorted to provide an enriched 
population of beta cells. Transgenic mouse islet cells can be separated into alpha 
and beta cells via expression of cell specific, genetic reporter molecules, 
however, these techniques are not applicable to islets isolated from human 
donors21-23. The latest method to purify individual islet cell subsets seeks to use 
cell surface markers that are specific to each islet cell subtype, similar to the way 
immunologic cells are isolated24. Grompe, Streeter, and colleagues have 
immunized mice with whole or dissociated human islets and collected 
hybridomas that demonstrate specific reactivity to alpha cells, pancreatic 
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endocrine or exocrine markers, and ductal cells. By staining human islets with a 
combination of these antibodies, this group can isolate specific populations of 
each islet cell subtype25,26.  
Each of these sorting methodologies essentially increases the concentration of 
alpha or beta cells from the heterogeneous mixture found in pancreatic islets, 
however, these techniques are not directly specific to any particular cell type. 
Granularity, zinc-composition, and combinations of nonspecific surface markers 
appear to enrich cell types of interest, but they do not provide pure populations. 
This report shows how a method designed to detect mouse alpha, beta, and 
delta cells based upon intracellular hormone content designed by Pechhold et al. 
has been adopted and optimized to isolate human islet cell subsets27. By 
dissociating human islets into a single cell suspension, fixing the cells to maintain 
intracytoplasmic content, and staining with insulin, glucagon, and somatostatin 
specific antibodies, exceedingly pure populations of beta, alpha, and delta cells, 
respectively, have been isolated. 
Methods 
Treatment of Islets 
Islet Distribution All human islets are received from the Integrated Islet 
Distribution Program (IIDP) coordinated by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK), the City of Hope, and a series of Islet 
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Isolation Centers situated within University Hospitals across the United States. 
The IIDP provides purity information and indicates the number of days the islets 
were cultured following isolation. Additionally, they provide demographic 
information such as gender, age, and BMI for each donor. 
Preparation Figure 2.1 provides a brief outline of islet treatment upon receipt: 
islets are dissociated into a single cell suspension, fixed and permeabilized, 
labeled with antibodies for intracellular hormones, and sorted using fluorescence 
activated cell sorting (FACS).  
Dissociation Islets are washed in Hank’s Balanced Salt Solution (HBSS – 
Mediatech (21-023, with calcium and magnesium) and sedimented at 1200 
revolutions per minute (rpm) for 4 minutes at 8°C. To begin dissociation, islets 
are first resuspended in 10 mM ethylenediaminetetraacetic acid (EDTA – 
Mediatech (46-034)) dissolved in phosphate buffered saline (PBS – Sigma 
(D8537)) and sedimented. The pellet is resuspended in 1 mL of PBS and 300 µL 
of trypsin/EDTA (1:50 dilution of 20µg/mL trypsin, 10 mM EDTA in PBS). This 
resuspension incubates for 10 minutes at room temperature and is pipetted up 
and down periodically to help loosen up the pellet into single cells. The pellet is 
washed in PBS, pelleted again, and resuspended in 1 mL PBS. An aliquot is 
stained with trypan blue to count the cells and assess viability.  
Fixation The cells are fixed at 4°C with 4% paraformaldehyde (PFA) for 5 
minutes prior to the addition of 0.1% saponin (Sigma – S47036). The cells, 
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fixation, and permeabilization buffers are incubated at 4°C for 25 minutes, prior to 
dilution with PBS. Cells are washed twice with PBS (spin at 1500 rpm, 5 minutes, 
4°C) in a polystyrene container. The increased speed and use of a polystyrene 
tube prevents cell loss. Finally, the cells are resuspended in wash buffer (WB) 
comprised of RNase-free 0.2% bovine serum albumin (BSA – Equitech 
(BAH67)), 0.1% saponin, dissolved in PBS, and distributed for staining.  
Intracellular Hormone Staining Prior to staining, all antibody buffers are incubated 
for 1 hour with RNase inhibitors vanadyl ribonucleoside complexes (VRC) and 
Murine RNase Inhibitor (New England BioLabs – M0314). Staining buffer 
contains 1% BSA, 0.1% Saponin, 7.5 mM VRC, and a 1:10 dilution of Murine 
RNase Inhibitor, all diluted in PBS. A chicken IgGY anti-bovine insulin antibody 
(ABI) manufactured by Gallus Immunotech is used to staining intracellular insulin 
hormone. The antibody is used at a 1:10 dilution in labeling experiments 
involving cells from greater than 1,000 islets and at a 1:25 dilution in studies with 
cells from fewer than 1,000 islets. Cells are stained for 25 minutes at 4°C and 
washed twice with WB. During the incubation step, the glucagon (Sigma – 
G2654) and somatostatin (GeneTex – GTX71935) antibodies are Zenon labled 
(Invitrogen) with Zenon Pacific Blue (PB) for Mouse IgG1 (Z25041) and Alexa 
Fluor 488 (AF488) for Mouse IgG1 (Z25002), respectively. Anti-glucagon is 
incubated in Zenon at 3.5 µg antibody/µL of Zenon and anti-somatostatin is 
incubated with Zenon at 2.4 µg antibody/µL. The Zenon labeling reaction is 
performed following the manufacturer’s instructions. Insulin-stained cells are 
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incubated with anti-glucagon labeled with PB and anti-somatostatin labeled with 
AF488 for 5 minutes at 4°C, followed by the addition of donkey anti-chicken 
allophycocyanin (APC) labeled secondary antibody (Jackson ImmunoResearch 
(703-136-155)) at a 1:16 final dilution. Cells are then washed twice with WB, a 
third time with PBS, and resuspended in 1% PFA. Cells are passed through a 
0.37 mm filter prior to sorting. 
Sorting Fluorescence activated cell sorting was performed in the University of 
Massachusetts Medical School Flow Core Laboratory using a BD Biosciences 
FACSAria II Cell Sorter. All fluorochrome, laser, dichroic mirror, and bandpass 
filter parameters and settings are listed in Table 2.1. 
Table 2.1 Flow Cytometer Settings 
 
This table describes the excitation and emission parameters for each 
fluorochrome and the flow cytometer settings used to detect each molecule.  
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Figure 2.1 Islet Cell Purification Flow Diagram The human islet is comprised 
of a heterogeneous mixture of alpha (α–GCG+), beta (β–INS+), delta (δ–SST+), 
and other cells, and they must be separated into individual populations before 
they can be studied independently28. We receive human islets from the IIDP, 
dissociate them into a single cell suspension, fix them with PFA, permeabilize 
them with saponin, and stain for intracellular hormone content. Using the 
hydrodynamic focusing mechanism of FACS, single cells are sorted into unique 
and pure populations. 
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Gating Hierarchy Figure 2.2 outlines the gating strategy used to isolate pure, 
single cell populations of human islet cell subsets. Debris is eliminated using a 
size gate in a forward scatter area (FSC-A) versus side scatter (SSC-A) plot 
(Figure 2.2A); particles outside of this gate are excluded from further analysis. 
Cells are next observed for insulin content in an APC (insulin) versus FSC-A plot 
(Figure 2.2B). All cells that form a distinct APC-positive population and can be 
distinguished from insulin negative cells are collected in the insulin gate. The 
cells excluded from the insulin gate (termed the inverse insulin gate) are plotted 
for PB (glucagon) versus AF488 intensity (somatostatin) (Figure 2.2C). All cells 
distinctly positive for PB or AF488 are collected in the glucagon and somatostatin 
gates, respectively. Doublets are excluded for each population by first observing 
each population on plot comparing FSC-Height (FSC-H) versus FSC-A. Doublet 
cells have a larger FSC-A component that does not correspond to the FSC-H 
component, due to their larger size, and they are consequently excluded from the 
insulin (Figure 2.2D) and glucagon (Figure 2.2E) positive cells. Second, the 
insulin positive cells are plotted against PB and AF488 (Figure 2.2F) and the 
glucagon positive cells are plotted against APC and AF488 (Figure 2.2G). The 
cells that are negatively labeled within each plot are the pure populations of each 
subset and they are dispensed for collection from the flow cytometer. 
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Figure 2.2 Fluorescence Activated Cell Sorting Gating Strategy Cells are 
sorted from a heterogeneous single cell suspension based upon their size, 
hormone content, and singlet nature. Viable cells are selected by gating out 
debris (A). Insulin positive cells are selected (B) and an inverse gate is used to 
identify glucagon and somatostatin positive cells (C). Doublets are excluded from 
insulin (D) and glucagon (E) positive cells. Double positive cells are eliminated by 
selecting against fluorophores that do not stain the population of interest – PB 
and AF488 for Insulin (F) and APC and AF488 for Glucagon (G). These 
populations are collected after sorting.   
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Results 
The plots provided are representative images collected on 06-February-2012 
(Figure 2.2 (A-G) and Figure 2.3 (A-C)) and 10-May-2012 (Figure 2.4 (A-C)). The 
cells that were collected on 06-February-2012 were subjected to further 
processing by RNA extraction and next generation sequencing (Chapter IV). 
Chapter III provides an analysis of each individual sort with respect to the alpha 
and beta cell composition and characterization relative to organ donor 
demographics. 
The gating hierarchy and sorting strategy provide different ways to confirm that 
the isolated populations are pure and distinct. Table 2.2 shows the number and 
percentage of events collected for each population at each stage of the gating 
process. The two-tiered doublet exclusion gating strategy eliminates 
approximately 30% of insulin positive cells comprised of sample that is either 
double positive for hormone expression or did not completely dissociate. To 
show the pure nature of the beta cell population, the sorted insulin positive cells 
can be plotted against the glucagon (Figure 2.3A) and somatostatin (Figure 2.3B) 
positive cells, which show how the three populations are separate and distinct. 
Furthermore, consistent with the granular nature of insulin secretory vesicles, 
beta cells display a higher side scatter component than alpha and delta cells 
(Figure 2.3C). To further confirm that the sorting step was successful, a small 
fraction of each sorted population was reanalyzed via flow cytometry, see Table 
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2.3. Sorted populations of alpha (Figure 2.4A) and beta (Figure 2.4B) cells show 
greater than 97% purity. Additionally, reanalysis of the cell population that did not 
demonstrate any insulin, glucagon, or somatostatin signal showed that positively 
stained cells were not lost during the sorting procedure (Figure 2.4C). 
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Table 2.2 Gating Hierarchy Example 
These tables show the number (top) or percentage (bottom) of events recorded 
for a whole islet analysis. The column titles correspond to the gating strategy 
described in Figure 2.2: inclusion in the size gate (A) and subsequent staining 
gates (insulin+ (B), glucagon+ (C), or somatostatin+ (C)), doublet exclusion 
(insulin+ (D), glucagon+ (E)), and single positive cells (insulin+ (F), glucagon+ (G)). 
Of the 26,079 cells (27% of total cells) that positively stained for insulin, 18,544 
(19% of total cells or 71% of cells that initially stained positively for insulin) would 
be collected as singlet cells that express only the insulin hormone.  
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Table 2.3 Purity of Reanalyzed Subsets 
This table shows the percentage of events for four samples and it corresponds to 
the data presented Figure 2.4. The unsorted sample is a heterogeneous mixture 
of insulin, glucagon, and somatostatin positive cells. Following sorting, a small 
fraction of the purified populations are reanalyzed to determine purity. 
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Figure 2.3 Fluorescence Activated Cell Sorting Islet Cell Subsets Gated and 
sorted cells are plotted to show individual populations (A, B) – insulin positive β 
cells (red), glucagon positive α cells (blue), and somatostatin positive δ cells 
(green). A traditional FSC versus SSC plot (C) shows that insulin positive cells 
have the highest degree of side scatter due to their granular nature.   
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Figure 2.4 Reanalysis of Purified Subsets Following sorting, cells were 
reanalyzed to assess the relative purity of each population. The stained, but 
previously unsorted heterogeneous mixture of islet cells was used to design the 
gates (top row). The remaining rows show the same gates and are used to 
analyze the purity of the Insulin positive (A) – 98% pure, Glucagon positive (B) – 
97.5% pure, and Unlabeled Cells (C) – less than 2.5% Insulin, Glucagon, or 
Somatostatin positive cells. The initial Somatostatin positive population is not 
shown. Please see Table 2.2 for a breakdown of subset population purities.  
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Discussion 
The heterogeneous nature of pancreatic islets has long confounded analysis of 
individual cell subsets. Using flow cytometry, researchers have tried to isolate the 
beta cell population by taking advantage of their intrinsic high granularity and 
insulin-associated zinc concentration as well as by screening for subtype specific 
cell surface markers. These techniques have allowed for beta cell enrichment, 
but have not provided pure populations of islet cell subtypes. Assessments of 
purity have compared insulin to glucagon mRNA levels, but have not measured 
protein expression in the selected cell types20,25,26. Additionally, human islets 
cannot be manipulated to express cell type specific fluorescent reporter 
molecules, as has been reported for mouse21,23.  
Using a mouse model, Pechhold et al. developed a flow cytometry sorting 
technique that capitalized on the hormone expression pattern specific to the islet 
cell subtypes27. Confocal scanning microscopy had previously been used to 
analyze the hormone content and architecture of human, nonhuman primate, and 
mouse islets28. These studies allowed for analysis of cell structure and 
arrangement within islets and provided a method for separating out individual cell 
types for further study. Dissociated islet cells were fixed and permeabilized prior 
to exclusively labeling alpha cells with a glucagon specific antibody, beta cells 
with an insulin specific antibody, and delta cells with a somatostatin specific 
antibody. Labeling with fluorescently conjugated secondary antibodies permitted 
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sorting and collection of the individual cell types by flow cytometry. Given our 
interest in studying human cells, we have shown that this technique can be 
applied to human islets isolated from cadaveric donors such that we obtain 
individual alpha, beta, and delta cell populations that are greater than 97% pure.  
The specificity and purity of alpha, beta, and delta cell populations highlight the 
major strength and advancement of this approach. Unlike with the other 
techniques, cells are sorted based upon the specific, intracellular hormone 
content and they represent a true isolation of a pure population, rather than just 
an enrichment. This method for sorting does have its drawbacks when compared 
to the other methods. Fixation and permeabilization result in a nonviable cell, 
following treatment. Cells sorted by surface marker labeling result in the isolation 
of viable cells that can be used in downstream experiments where attempts are 
made to culture or reprogram the enriched cell types13,29,30.  
One of the major reasons for performing isolation of islet cell subsets centers on 
performing gene expression analysis. To conduct these studies (quantitative real 
time polymerase chain reaction (qRT-PCR or qPCR), microarray analysis, next 
generation sequencing), RNA must be isolated from the cells. White and 
Kaestner (2009) discuss how it is difficult to obtain pristine RNA from the 
pancreas due to the endogenous presence of RNA degradation enzymes 
(RNases)14. This technique compounds this problem by fixing and permeabilizing 
the cell, which can introduce exogenous RNases (from buffers and antibodies) to 
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intracellular stores of RNA, resulting in the degradation of the most valuable 
resource. To overcome the issue of not having the full-length, intact RNA needed 
for more global qPCR or microarray studies, and turn a weakness into a strength, 
Pechhold and colleagues used a quantitative nuclease protection assay (qNPA) 
that could measure the expression levels of small, 50 nucleotide sequences of 
RNA. As will be discussed in Chapter IV, we have used this qNPA technique and 
optimized our staining and sorting protocol to attempt next generation 
sequencing of these sorted cells. By devloping this technique, we hope to make it 
possible to first establish the gene expression profiles (i.e. transcriptome) for 
individual islet cell populations. Second, we aim to measure how these profiles 
change in different donors, upon exposure of the islets to various stimuli that may 
promote proliferation Finally, we aim to pursue these same studies in a more 
controlled non-human primate (NHP) model system that more accurately 
replicates human islet morphology and physiology. 
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CHAPTER III 
EPIDEMIOLOGY OF HUMAN ISLET COMPOSITION 
Introduction 
The islets of Langerhans are heterogeneous clusters of multiple hormone 
producing cell types that comprise the endocrine pancreas. Glucagon producing 
alpha cells, insulin producing beta cells, somatostatin producing delta cells, 
pancreatic polypeptide producing gamma cells, and ghrelin producing epsilon 
cells function in a coordinated fashion in order to maintain whole body glucose 
homeostasis31. Mouse islets are the most well-studied and demonstrate an 
arrangement where the beta cells form a core in the center of the islet, while the 
remaining four cell types surround this organized concentration of insulin 
producing the cells via an indiscriminate peripheral arrangement28,31.  
Compared to rodents, islets isolated from nonhuman primates and humans 
display a more variable islet structure in terms endocrine cell arrangement and 
relative ratios 28. In these islets, alpha, beta, and delta cells are intermingled and 
can be found throughout the islet, both in the core and on the surface. Using 
laser scanning confocal microscopy through the whole islet, Brissova and 
colleagues showed that the beta cells are often found at the exterior of the islet28. 
Although their studies did not distinguish how islet structures changed within 
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different locations in the pancreas, each of the individual islets isolated 
demonstrated a similar heterogeneous pattern.  
Both laser scanning confocal microscopy and analysis of histological sections 
have been used to compare the relative amounts of alpha, beta, and delta cells 
in the pancreatic islet. Similar to the structural differences, mouse and human 
islet composition shows different percentages of each cell type, with increased 
variability found in human islets. While mouse islets contained a vast majority of 
beta cells (75%, range 65-85%), the beta cell average in human islets was closer 
to half of the stained endocrine cell population (54%, range 30-75%) with a much 
wider variation among donors. Similar observations were found in alpha cells 
(19%, range 10-30% in mouse versus 35%, range 10-65%in human) and delta 
cells (6%, range 2-10% in mouse versus 11%, range 2-22% in humans)28,31-33.  
Given our intracytoplasmic staining of insulin, glucagon, and somatostatin 
proteins and analysis by flow cytometry, we aimed to show that our results for 
human islet composition was equally variable in showing the range of alpha, 
beta, and delta islets in donor islets. Additionally, we used the demographic 
information provided by the IIDP to assess how islet culture time and donor age, 
gender, and BMI affected the beta to alpha cell ratio in human islets. 
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Methods 
Human islets were dispersed, fixed, stained, and sorted as described in Chapter 
II. Demographic information was collected from the IIDP donor information 
packets that generally included donor gender, age, BMI, history of diabetes, and 
duration of islet culturing prior to shipment. Total alpha, beta, and delta cell 
numbers were calculated from single stain analysis for insulin, glucagon, or 
somatostatin protein expression or from total stains that were simultaneously 
sorted for all three hormones. Results are presented as the percentage of each 
labeled cell subset (percentage of total labeled cells that are either insulin, 
glucagon, or somatostatin positive) or by comparing the ratio of beta to alpha 
cells in each given preparation. A two-tailed student’s T-test was used to make 
all statistical comparisons: percentage or ratio of beta to alpha cells in all staining 
experiments, or stratified by gender, age, BMI, and days in culture. Power and 
sample size calculations were made using Java Applets for Power and Sample 
Size, an alpha error value of 0.05, and the data provided in Table 3.1, Figure 3.1, 
and Figure 3.234.  
Results 
Islet Composition Islet samples from 18 donors were analyzed via flow cytometry 
for glucagon and insulin content, 11 were also assessed for somatostatin 
content.  Table 3.1 provides the demographic information for the donors and 
shows the percentage of positively labeled flow cytometry events that stained for 
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glucagon, and insulin positive cells. The population was 39% female, had an 
average age of 38.4 years, BMI of 30.3 kg/m2, and 53.7% of total flow cytometry 
events corresponded to positively stained endocrine cells. Figure 3.1 shows the 
composition of the positively labeled cells: 41% (range 23 – 58.8%) stained 
positively for glucagon and are referred to as alpha cells, 54% (range 38.4 – 
71.7%) stained positive for insulin and are referred to as beta cells, 5% (range 
2.7 – 10%) stained positively for somatostatin and are referred to as delta cells. 
Using the data in Table 3.1 and an alpha error level of either 0.05 or 0.01, the 
power of this experiment is 0.95 or 0.82 respectively. As such, it is adequately 
powered to calculate the percentage of islet cells that are glucagon- versus 
insulin-positive. 
Beta to Alpha Cell Ratios and Composition among Demographics Given the 
variability of the alpha and beta cell proportion of each islet donor, the beta to 
alpha cell ratio provides a way to examine how islet composition compares 
across the limited demographic groups. Within the whole donor population, the 
beta/alpha ratio is 1.49 (range 0.65 – 3.12). Islet donors were sorted into groups 
based upon gender (male, n=11 or female, n=7; Figure 3.2A, B), age (under 40, 
n =9 or over 40 n =9; Figure 3.2C, D), BMI (25 and under, n=5 or over 25, n=13; 
Figure 3.2E, F), and days in culture (under 3 or over 3; Figure 3.2G, H). No 
significant difference (p-value < 0.05) was found within the gender, BMI, and 
days in culture groups. Currently, these experiments are not adequately powered 
to judge overall significance: gender (power = 0.47; n for each group >16 needed 
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for power >0.8), age (power = 0.68; n for each group >12 needed for power 
>0.8), and BMI (power = 0.35; n for each group >29 needed for power >0.8). 
Islets from female donors, however, tended to contain more Insulin+ cells (Figure 
3.2B) than male donors. Additionally, donors with higher BMI values displayed 
more variability in their islet composition (Figure 3.2F) than donors who displayed 
suggested BMI levels (less than or equal to 25 kg/m2).  
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Table 3.1 Islet Donor Demographics 
 
Average is reported with (standard deviation). *p-value is calculated using an 
unpaired, two-tailed, t-test and compares the female and male populations. Note: 
for whole sample, %Glucagon+ versus %Insulin+ p-value = 0.0008.  
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Figure 3.1 Human Islet Composition – Endocrine Cells Islets were stained 
with antibodies that recognize intracellular hormones glucagon (α-cells), insulin 
(β-cells), and somatostatin (δ-cells). The sample number, mean, and (standard 
deviation) are provided for each cell subset. β-cells comprise a higher 
percentage of labeled endocrine cells than do α-cells. Both α- and β-cells are 
expressed at a significantly higher level than δ –cells (p < 0.0001).  
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Figure 3.2 Human Islet Composition Across Demographic Variables Islet 
composition was converted to a beta/alpha cell ratio and plotted (A, C, E, G) or 
plotted as % Glucagon+ and % Insulin+ for each of the 18 analyses (B, D, F, H). 
Among the observed demographic variables, Gender and Age show significant 
differences between the beta/alpha cell ratio (C) and % Glucagon+ and Insulin+ 
between the two demographic groups (B, D). Donor BMI does not have 
significant difference on either islet measure (E, F). Technically speaking, the 
number of days islets are in culture does not change the beta/alpha cell ratio or 
the percentage of Glucagon+ or Insulin+ cells (G, H). 
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Discussion 
Human islet composition, viability, and quality are important factors to consider 
when assessing whether or not an islet preparation is appropriate for transplant 
into a type 1 diabetic patient8,9,35,36. It also speaks to the difficulty with using 
human samples in research studies. Gene expression of whole islets could vastly 
differ from donor to donor based upon the relative proportions of the 
heterogeneous cell types that comprise each particular islet donor who may be a 
different age, gender, weight, have different health conditions, or whose islets 
may have been isolated and cultured by a different isolation team for various 
periods of time8,14,27,37. Sorting by flow cytometry allows for the separation and 
examination of each cell type in terms of total islet composition and individual 
gene expression qualities. 
These results show that analysis of single cell suspensions of human islets by 
flow cytometry detect the donor to donor variability equally as well as confocal 
microscopy28. This report details the cellular composition of human islets isolated 
from 18 donors, shows a similar characterization of heterogeneous variability as 
detected by confocal microscopy and histological staining, and further begins to 
examine whether or not there is a pattern to the factors that contribute to islet 
variability.  
On average, it does appear that human islets have a higher percentage of beta 
cells to alpha cells, both of which far outnumber the contribution of delta cells to 
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whole islet composition. We found that of all events measured by the flow 
cytometer, an average of greater than 50% corresponded to positively labeled 
endocrine cells. This number could be lower than expected due to a wide spread 
of islet purity or a variable expression of insulin and glucagon within alpha and 
beta cell populations that may preclude clearly differentiating positively labeled 
cells from the background population. We have observed what appear to be two 
populations of insulin expressing cells following flow analysis. Restaining of cells 
that appear to be negative for endocrine cell markers with another insulin 
antibody shows that they do contain a portion of low expression insulin positive 
cells (data not shown). 
The small sample size is a limitation in correlating the data with the broad range 
of the population. Based on the demographic information that is known, however, 
we were able to observe some statistically significant differences in beta/alpha 
cell ratios and other results that are trending in one direction versus another. 
First, it does not appear that the number of days in culture affects the beta/alpha 
cell ratio across donors. Different donor islets cultured for less than or greater 
than three days showed approximately the same beta/alpha cell ratio, however, 
we favor the more recently isolated islets. There is a trend toward a higher 
beta/alpha cell ratio in female donors. It was interesting to note the uniformity of 
the beta to alpha cell ratio in young (less than 40 years of age) donors. While this 
ratio was found to be about 1:1, donors over 40 years of age had almost two 
times more beta cells than alpha cells. Unfortunately, we cannot determine the 
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total number of beta or alpha cells isolated from each of these populations, 
however, the change in ratio is indicative of more insulin expressing cells. BMI 
does not appear to affect the beta to alpha cell ratio in a significant fashion, 
consistent with previous studies38,39, although there is a trend toward a higher 
contribution of beta cells at higher BMI values. With more samples, we could 
more closely investigate the connection between age and BMI to determine if the 
older patients with high BMI had the highest (or lowest) beta to alpha cell ratios, 
which might explain pre-diabetes or undiagnosed type 2 diabetes38,40.  
This analysis shows that flow cytometry and hormone staining accurately 
measure human pancreatic islet composition. Human islets display a great 
degree of heterogeneous variability from donor to donor, not noticed in mice, and 
these differences could be attributed to the age, gender, or BMI of the donor 
subject. By analyzing and sorting these cells with flow cytometry, we obtain pure 
populations of each cell type, which can be used for downstream gene 
expression analysis and future comparisons. 
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CHAPTER IV 
GENE EXPRESSION EXPERIMENTS & PROFILING RESULTS 
Introduction 
The arrangement and organization of the pancreatic islet has made it difficult to 
isolate unique populations of islet cell subtypes with intact RNA. Islets comprise 
less than 5% of total pancreas tissue and are located amongst exocrine tissue 
that contains numerous digestive enzymes and RNases1,14. As a result, human 
islets must first be separated from this largely irrelevant tissue, a process 
performed by hospital centers associated with the IIDP. Although these islet 
preparations are generally 80% pure, they do contain acinar tissue, ductal cells, 
and other debris that must be removed prior to separation. Finally, the 
heterogeneous construction of islets means that they must be dissociated into a 
single cell suspension prior to treatment and analysis. Up until this point, 
however, it has been difficult to obtain pure populations of alpha and beta cells 
that contain high quality RNA14.  
As was described in Chapter II, and throughout this thesis, we have developed a 
cell sorting strategy that allows us to separate pancreatic islets into their 
individual, pure, subset populations. Following intracellular hormone staining, we 
can obtain pure populations of alpha, beta, and delta cells. By understanding the 
specific cellular transcriptome of a cell type of interest, the molecular and cellular 
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controls that guide development and disease states can be investigated41. As an 
example, this chapter recounts how we stimulated human islets with exogenous 
glucose and an incretin mimetic, exenatide. By studying changes to the 
transcriptome, we can identify proteins, regulators, and pathways involved in 
biological processes such as increased glucose stimulated insulin secretion, 
glucagon inhibition, beta cell proliferation, and insulin resistance. This strategy 
will help us to understand the processes that might improve islet transplant 
success or more effectively treat or prevent type 2 diabetes.  
This chapter will show how we initially used the qNPA to overcome the RNA 
quality limitation that prevents qPCR, microarray analysis, and next generation 
sequencing analysis. Second, we will show how we have streamlined the sorting 
and RNA extraction procedure in order to improve RNA quality. In this regard, we 
have successfully performed next generation sequencing on RNA extracted from 
purified beta cells and have worked to overcome the previous limitations that 
prevented gene expression analysis in human islets and islet cell subtypes.   
Methods 
Human islets were dispersed, fixed, stained, and sorted as described in Chapter 
II. Following sorting, pure populations of cells were treated in accordance with 
the protocol associated with the downstream assay. 
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HTG Lysis Sample Preparation for qNPA Cells were washed with PBS, 
sedimented at 1500 revolutions per minute (rpm) for 4 minutes at 8°C, and 
decanted. Cells were resuspended in lysis buffer supplied by HTG Molecular 
Diagnostics at greater than 200 cells/µL and frozen at -80°C until further use. 
Samples were subjected to qNPA as described previously27. Briefly, sorted cell 
lysates are incubated with gene specific 50 nucleotide probes and anneal with 
complementarity. S1 nuclease is used to digest unbound probes and mRNA and 
alkaline hydrolysis removes bound mRNA, to leave only the gene specific probe. 
The probes are transferred to the qNPA plate. The qNPA plates are designed so 
that each well has a 4x4, gene-specific, grid map printed on it. Each spot within 
the well corresponds to a specific gene and is programmed with linkers that 
recognize one of the 16 respective spots. The sample qNPA probes are added 
and binds to the programming linker. The detection linker hybridizes to the probe 
and the detection probe binds to it. After incubation with HRP substrate, photons 
are measured using the HTG Omix HD. Photon exposure is measured for 15, 30, 
and 60-second intervals. During data analysis, results are normalized to intensity 
per 1,000 cells per minute of exposure time. Genes that saturate the detector 
upon initial measurement are normalized by measuring the signal decay of genes 
within the dynamic range over 30, 60, and 120 minutes, and adjusted 
accordingly.  
Exenatide Experiments Human islets were incubated overnight in culture with a 
titration of glucose and exenatide included within the culture medium. CMRL was 
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prepared with 5.5 mM D-glucose, 1x sodium pyruvate, 1x nonessential amino 
acids, and 10% fetal bovine serum (FBS). Control and 100 mM exenatide wells 
were cultured with 5.5, 8, or 16 mM final glucose concentration. Following 
overnight incubation, islets were removed from each well and processed as 
described previously. 
Preparation for RNA Extraction Sorted cells were washed with PBS, sedimented 
at 1500 rpm for 4 minutes at 8°C, and decanted. Cell pellets were next treated 
according to the protocol described by the Qiagen formalin fixed paraffin 
embedded (FFPE) RNeasy Kit, starting at step 6, which disregards the 
deparaffination steps. In brief, pellets are resuspended in 150 µL of buffer PKD 
and 10 µL of proteinase K. Cells are incubated at 56°C for 15 minutes followed 
by 5 minutes at room temperature before a second incubation at 80°C for 15 
minutes. Following a 3 minute incubation on ice, cells are spun at 13,200 rpm for 
15 minutes at 20°C and the supernatant is removed and frozen at -80°C until 
further processing. Total RNA (greater than 18 nucleotides in length) is isolated 
using the QIAGEN miRNeasy FFPE kit (note: the sole difference between these 
two kits involves the concentration of ethanol mixed with the RNA during the 
binding step; the higher the ethanol concentration, the greater the affinity of the 
RNA for the column, which allows the microRNA species to bind and be isolated 
simultaneously with the total RNA). Briefly, cells are treated with DNase, 
incubated with an RNA binding buffer and 100% ethanol, spun through the 
RNeasy MiniElute Spin Column, washed with a QIAGEN buffer, spun without any 
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buffer to remove excess ethanol, and eluted in 30 µL of RNase Free water. 
Following elution, RNA is analyzed using the Agilent BioAnalyzer to assess RNA 
quality and concentration. Depending on the concentration of the RNA, it is 
analyzed on a pico (less than 5 ng/µL) or nano (greater than 5 ng/µL) chip. 
microRNA Analysis HTG qNPA technology was used to obtain microRNA 
(miRNA) array data for alpha and beta cells. Following sorting of alpha and beta 
cell populations from two donors (a 20-year-old female with a BMI of 19 kg/m2 
and a 50-year-old male with a BMI of 25 kg/m2), whole cell lysates were sent to 
HTG for processing via a miRNA specific qNPA chip) representing ~1,050 
miRNA species (Sanger miRBase release 9.1). Each sample population was run 
in duplicate and miRNA species were only chosen to be positively expressing if 
both duplicates had signal intensity values above the negative controls within that 
specific experiment. In this way, we worked to eliminate false positive 
identifications.  
Next Generation Sequencing RNA samples were shipped on dry ice to Beijing 
Genomics Institute (BGI) for library construction, validation, and sequencing. The 
BGI protocol for library development, normalization, and preparation mirrors the 
protocol described by Danos et al42. Briefly, RNA is digested with DNaseI and 
purified. RNA is fragmented followed by first and second strand cDNA synthesis 
and purification. Ends are repaired, adenylated, ligated to adaptors, and purified 
again. PCR amplification is completed using a pair of inner primers and the 
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library is validated. The library is then normalized with double strand nuclease 
(DSN) to remove a fraction of genes that are overexpressed. Following a final 
amplification using paired end primers, the library is purified, assessed for 
quality, and submitted for sequencing using the Illumina HiSeq2000, which is 
equipped to produce greater than 20 million 91 base pair, paired end reads of 
each library sample.  
Results 
qNPA Gene Detection The gene expression profiles of sorted alpha and beta 
cells were determined using the qNPA. Alpha cells were found to express PPIA, 
insulin, glucagon, PPY, CD2, Pax6, and β-actin, however, somatostatin, ngn3, 
amylase, CK19, Pax4, MafA, MafB, and p48 were not detected. Beta cells were 
found to express PPIA, insulin, glucagon, somatostatin, ngn3, PPY, CD2, Pax6, 
MafA, and β-actin, however, amylase, CK19, Pax4, MafB, and p48 were not 
detected (see Table 4.1 and Figures 4.1). In alpha cells, the glucagon gene 
expression level was found to be 72-fold higher than the insulin expression level; 
similarly in purified beta cells, the insulin glucagon gene expression level was 
found to be 101-fold higher than the glucagon expression. 
Incubation with exenatide and glucose did not appear to have any effect on the 
relative proportions of alpha and beta cells in culture (Table 4.2). Across the four 
experiments, the relationship between the insulin to glucagon ratio at day zero 
did not consistently vary with the ratio calculated after overnight culture. Gene 
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expression changes in alpha cells were not detected as represented by glucagon 
(Figure 4.2A) and PPY (Figure 4.2B) gene expression levels across all glucose 
and exenatide concentrations. Unlike insulin (Figure 4.2C) and other beta cell 
genes, we detected increased expression of PPY in beta cells that correlated 
with increased glucose and exenatide concentration (Figure 4.2D). All gene 
expression levels were normalized to total plate intensity. 
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Table 4.1 Gene Expression Values for sorted Alpha and Beta Cells 
 
 
Following completion of the qNPA, gene expression values for each gene in the 
purified alpha and beta cell populations were recorded using qNPA intensity units 
per minute, per 1,000 cells. n.d. indicates that the gene was not detected. 
Although this experiment was conducted four times, variations in initial runs of 
the control lane compromised the ability to compare raw values across runs. As a 
result, this table represents an average of two technical replicates for a 
representative experiment.  
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Table 4.2 Islet Composition upon Exposure to Increased D-glucose and/or 
Exenatide 
 
 
Whole islets were dissociated, fixed, and stained as described previously 
immediately upon receipt (Day 0) or following a 20 hour overnight culture in 
glucose and exenatide as indicated: CMRL describes the culture media, (mm 
DG) describes the glucose concentration, and EX indicates that 100 mM 
exenatide was included within the incubation. Flow cytometry of each sample 
provided the necessary data to calculate the percentage of glucagon, insulin, or 
somatostatin positive cells. This experiment was conducted four times. Due to 
the variability in islet cell composition (as demonstrated in Figure 3.1), this table 
corresponds to one representative experiment. 
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Figure 4.1 Gene Expression Values for sorted Alpha and Beta Cells The 
expression levels of the 15 genes listed in Table 4.1 were examined in sorted 
alpha (A) and beta (B) cells using the qNPA technique. The hormone specific to 
each subpopulation is the most widely expressed gene in each sample 
(Glucagon – A; Insulin – B). Glucagon is expressed at a 72-fold higher intensity 
than insulin in purified alpha cells. Similarly, insulin is expressed at a 101-fold 
higher intensity than glucagon in purified beta cells. These data serve as a 
representative image. 
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Figure 4.2 Effect of [D-Glucose] and Exenatide on Gene Expression Human 
islets were incubated in increasing [D-glucose] plus or minus exenatide. 
Glucagon and insulin gene expression remained unchanged (A and C) in alpha 
and beta cells respectively. Additionally, PPY (B) expression did not change in 
alpha cells, however, it showed an increase in beta cells (D) in response to 
incubation with exenatide and increased [D-glucose].  
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RNA Quality RNA has been isolated from dissociated whole islets and sorted 
alpha, beta, and unlabeled cells using multiple derivations of the Qiagen RNeasy 
kits. We have always been able to obtain RNA with an RNA Integrity Number 
(RIN) greater than 7 from whole, dissociated islets that have not been fixed, 
stained, or sorted (Figure 4.3A). Once islets are fixed, stained, and sorted, 
however, RNA extraction requires the RNeasy or miRNeasy FFPE kits. 
Additionally, we have found that RIN values suffer if RNA is washed in PBS and 
frozen (Figure 4.3B), resuspended in HTG or RLT lysis buffer and frozen, or if 
staining takes place in the absence of both VRC and recombinant RNase 
inhibitors. When staining takes place in the presence of both RNA inhibitors and 
following sorting, RNA is treated with proteinase K and heat, RIN numbers 
improve and 18S and 28S ribosomal RNA (rRNA) peaks can be detected 
following analysis on the Agilent Bioanalyzer. Although they vary from 
preparation to preparation, when working with approximately 200,000 sorted 
cells, we have consistently found RIN values greater than 3 and RNA yields 
greater than 200 nanograms in samples treated in this streamlined fashion 
(Figures 4.3C-D and Table 4.3). In the preparations we have used for RNA 
extraction and next generation sequencing analysis, we have been able to collect 
between 100,000 and 200,000 purified alpha and beta cells from approximately 
10,000 islets, which provides a sufficient amount of RNA for next generation 
sequencing.  
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Table 4.3 Sorted Cell RNA Quantity and Quality 
 
All islet RNA was isolated from the same donor and cell populations were sorted 
as shown in Figure 2.3. The donor was a 24-year-old male with a BMI of 29.2 
kg/m2. 
*Alpha Cell RNA quantity is estimated. BGI calculated quantity of Whole Islet, 
Beta Cell, and Unlabeled Cell RNA to be approximately 5 times higher than 
measured here. As a result, Alpha Cell RNA quantity from this donor meets the 
necessary threshold and is now in processing for sequencing analysis. 
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Figure 4.3 RNA Quality of Human Islet Cell Subsets Human islets were 
received from IIDP (donor 24 year old male with a BMI of 29.2 kg/m2) and sorted 
via intracellular staining. RNA was extracted from whole islets prior to fixation (A), 
following fixation, staining, sorting, and freezing of the beta cell population (B), 
and following fixation, staining, sorting, proteinase K treatment, heat 
demodification, and freezing of the beta cell population (C) and alpha cell 
population (D). RNA quality and quantity were analyzed using a Pico chip on the 
Agilent Bioanalyzer 2000. The Bioanalyzer calculates the RIN Value based upon 
the intensity of the 18S and 28S ribosomal RNA peaks. 
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microRNA Analysis Panels A and B of Figure 4.4 show a comparison between 
the miRNA expression levels between alpha and beta cells in each donor (alpha 
versus beta in 20-year-old R2 = 0.85; in 50-year-old R2 = 0.77) as observed using 
the HTG Molecular miRNA qNPA chip. We found 22 miRNA species that were 
expressed at a greater than two fold difference in alpha versus beta cells in both 
samples. Additionally, we found 9 miRNA samples expressed at a greater than 2-
fold difference across the two cell types to be unique to the 20-year-old donor 
and 15 miRNA samples to be unique to the 50-year-old donor.  Panels C and D 
of Figure 4.4 show the similarity in miRNA expression across two alpha and beta 
cell populations. The expression levels for each miRNA species were plotted 
against each other for alpha cells (R2 = 0.902) and beta cells (R2 = 0.976). A 
comparison between the two samples shows that the alpha cells from the 50-
year-old donor significantly (p ≤ 0.05) expressed 4 miRNA species at a 2-fold 
higher level than the alpha cells from the 20-year-old donor and 3 species at 2-
fold lower level. Within the beta cell population, only 2 species were expressed at 
significantly higher expression level in the 50-year-old. All miRNA expression 
levels can be found in the online Appendix (Table A.1). 
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Figure 4.4 miRNA Profiling Results miRNA profiles are provided from two 
donors comparing the α- versus β-cell miRNA profiles from donor 1 (20 year old 
female, BMI 19 – A) and 2 (50 year old male, BMI 25 – B) and the two unique α-
cell (C) and β-cell (D) populations. miRNA expression values were obtained 
using a qNPA chip (HTG Molecular) representing ~1,050 miRNA species 
(Sanger miRBase release 9.1). There were greater differences in miRNA 
expression levels within the α-and β-cell populations from the same donor; 22 
miRNAs were found to be expressed at a  >2-fold change in the individual cell 
types (A and B). The two donors showed similarity in miRNA expression levels 
among the α-cell (R2 = 0.90 – C) and β-cell (R2 = 0.98 – D) populations.  
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Next Generation Sequencing Results Our first sequencing sample has been 
analyzed by BGI and we have examine RNA isolated from whole islets, beta 
cells, and unlabeled cells. We have worked with the UMASS Bioinformatics Core 
to assess the data; the analysis presented here were created following core 
analysis of our raw data. 
We generated greater than 23 million, 91 base pair, paired-end reads for each 
islet cell sample. Of these reads, greater than 60% of whole islet and beta cell 
sequences match gene sequence and approximately 20% and 40% of these 
gene reads match to protein coding exons in the beta and whole islet cell 
populations, respectively, see Table 4.4. Using pathway and gene set enrichment 
analyses, we are able to determine which genes are up or down regulated in the 
beta cell fraction versus whole islets43. We find that transcription factors such as 
PDX1, PAX6, and MAFA are enriched in the purified beta cell population versus 
the unsorted whole islets, see Table 4.5. Within the beta cell population, we 
found the insulin gene to be expressed at 170-fold higher intensity than the 
glucagon gene. Of the 18,840 genes detected, glucagon ranked 18,804 and 
somatostatin ranked 18,838 in terms of relative gene expression in the beta cell 
versus the whole islet. An entire list of genes expressed in beta cells, whole 
islets, and the unlabeled cells, as well as their relative expression levels 
(expressed in Reads Per Kilobase transcriptome per Million mapped reads 
(RPKM)) can be found in the online Appendix (Table A.2)44. Values were 
normalized following orthogonal straight line fit regression analysis using raw 
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read values to compare genes specifically detected in the beta cell population 
versus those only detected in whole, unsorted islets.  
 
Table 4.4 Transcriptome Sequencing Mapping Results 
 
RNA extracted from whole human islets (that were not fixed, stained, or sorted), 
purified beta cells, and unlabeled cells from the same donor (24-year-old male, 
BMI 29.2 kg/m2) was subjected to next generation sequencing using the Illumina 
platform as described in the methods. This table provides the total number of 
reads generated for each sample and calculates the % of the reads that map to 
coding RNA and the gene (including a breakdown of intron versus exon regions; 
note intron and exon regions may overlap in reads that analyzed pre-mRNA 
species).   
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Table 4.5 Gene Set Enrichment Analysis of Top Beta Cell Genes 
 
A gene set enrichment analysis was performed to identify pathways in which a significant number of genes were 
enriched in beta cells versus whole, unsorted islets. The genes listed are representative of those categories and 
the table provides overall rank and exon length for each gene (identified by symbol and gene ID). Raw reads 
correspond to the number of reads measured by the sequencer. Normalized RPKM reads can be calculated as 
follows (e.g. INS, Beta Cells: !"#" !"#$%&%$ !"#$%∗!"!(!"!#$ !"#$%∗!"#$%!$&'!)/!""" ∗ 0.037, where 78,710 is the number of insulin specific 
reads, 24,371,357 is the number of total reads, 644 is the exon length, and 0.037 is the universal normalization 
factor calculated by orthogonal straight line fit regression analysis.
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Discussion 
These results provide the overall message that human islets can be sorted into 
individual cell subsets and gene expression can be measured. The qNPA 
technique allows us to measure gene expression changes on a customized, 
preselected number of genes. The next generation sequencing results currently 
provide us with a transcriptome that lists the genes expressed along with relative 
expression values within each cell subset. These two observations extend work 
done with sorted mouse islets with regard to measuring gene expression 
changes27. They also extend previous studies that were focused on the whole 
islet and due to technological limitations, could not determine gene expression or 
gene expression changes within individual islet cell subsets14,37,45. In this way, 
these studies have provided a new technique and technology to understand the 
genetic changes responsible for observed phenotypes of beta cell function, 
proliferation, ineffectiveness, and destruction. By understanding which genetic 
changes are specifically happening within a beta cell, we will better be able to 
characterize and understand how a beta cell functions and is regulated. 
The qNPA technique offers a powerful method for measuring changes in gene 
expression levels across multiple conditions using RNA that has been partially 
degraded and fragmented due to its endogenous environment and the cell 
sorting protocol. This technique measures gene expression directly from mRNA 
present in cell lysate. There is no need to extract RNA, convert it to cDNA, 
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amplify it, or otherwise treat the raw material in such a way that could cause RNA 
loss or bias the results27. There is no need for enrichment of RNA via selection of 
polyadenylated tails found on full length mRNA or depletion of unwanted 
ribosomal RNA that could compound the ability to measure genes expressed at 
low levels. The lack of selection and amplification prevents PCR biases against 
genes that are expressed at low levels (and are thus unable to be properly 
represented due to fold changes that exceed the dynamic range of measure 
technology). Since the assay readout is dependent upon detection probes 
specifically designed to multiple nucleotide sequences specific to the gene of 
interest, unwanted material is not measured without needing to be removed.  
In this study, we have shown the ability to measure consistent levels of insulin 
and glucagon gene expression in beta and alpha cells, respectively, following 
treatment with an insulin secretagogue. Interestingly, the expression of 
pancreatic polypeptide is found to be upregulated in beta cells (but not alpha 
cells) treated with this same drug. Although we have not taken the next step, the 
identification of a change in a beta cell specific gene expression pattern in 
response to an external stimulus represents the power of the methodology. It 
sets us up to pursue hypothesis driven cell and molecular biology experiments in 
beta cells. 
The qNPA suffers from its limited gene detection ability per assay, as the chips 
we designed could only measure 16 genes per assay; with a negative control 
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and two housekeeping genes amongst each detection. Given our interest in 
studying insulin and glucagon expression, this technique is also limited by its 
dynamic range and saturation by the most highly expressed genes. Reducing cell 
numbers per assay would preclude the detection of lower expressing genes. 
Additionally, changes within company infrastructure have also led to this 
technique becoming more expensive and the support staff less responsive. 
Although this technique has a lot of potential, the inability to rapidly (within 3 
months) and inexpensively expand and change assays is a major limitation at a 
time when new gene expression patterns, observations, and questions arise 
quickly. 
The next generation sequencing technique provides the ability to indiscriminately 
determine all of the genes that are specifically expressed in a particular cell 
population41,46,47. When using next generation sequencing, RNA quality is an 
important factor to consider. Much like PCR, isolated RNA must be extracted, 
converted to cDNA, prepared for sequencing, and then sequenced using the 
Illumina HiSeq2000. In initial studies, RNA quality had to be pristine in order to 
selectively enrich for mRNA (via polyA tail isolation) and selectively remove 
contaminating rRNA and tRNA (using various nucleotide sequences to subtract 
unwanted RNA from the total sample). Without full length RNA, these two 
techniques were not possible because unwanted reads easily outnumbered 
desired mRNA and the technological limitations of the number of reads that could 
be acquired per sample were prohibitive. As the technology has improved, costs 
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have decreased, the problematic RNA can be reduced via alternative techniques, 
and all mRNA can be read due to increasing the shear number of reads. This 
change has opened up next generation sequencing for samples such as ours, 
where the RNA is degraded and cannot be pretreated to enrich for only mRNA 
species42. These same problems can compromise the ability to perform 
quantitative PCR and microarray experiments and set next generation 
sequencing apart as a method for exploring transcriptomes14. While whole 
human islets have previously been subjected to next generation sequencing 
analysis, transcriptome analysis of purified alpha and beta cell populations has 
not been possible48.  
At the beginning of this study we were able to successfully isolate alpha and beta 
cell populations from whole islets, but RNA quality was still subpar. Through 
testing and limiting the RNA degradation that occurred during sample processing 
and streamlining the RNA extraction protocol to occur in a single day using a kit 
designed for FFPE samples, we have successfully isolated RNA of acceptable 
quality that is both unique to a specific cell subset and of adequate quality for 
RNA sequencing. The DSN treatment provides one of the major limitations of 
these studies. While treating with DSN is incredibly helpful in order to reduce 
contaminating rRNA sequence, it also reduces the total amount of sequence for 
genes that are naturally highly expressed in these cell subsets (read: insulin and 
glucagon as well as some housekeeping genes that are expressed at robust 
levels)42. This technique is beneficial because it allows us to detect even the 
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most lowly expressed genes by providing the read depth to measure those 
transcripts that would generally fall outside of the dynamic range of expression. 
The unfortunate consequence of this technique is that true quantitation has been 
compromised. We can still provide relative expression levels based upon the 
reported RPKM values, which allows for determining which genes are highly 
enriched in one sample versus another. We cannot, however, provide the 
absolute quantitative differences between two different genes, which would make 
precise measurement of gene expression levels across multiple environmental 
stimuli difficult. We are still working to determine if a change in the RNA quality 
isolated from whole, unsorted islets differs from whole, unsorted islets that 
undergo fixation, staining, and hydrodynamic focusing, but are not actually 
sorted.  
At the writing of this thesis, we have shown that we can sequence RNA from 
sorted beta cells. Sequencing coverage appears to be fairly complete, as overall 
gene sequencing does not favor either the 3’ or 5’ end across single genes. 
Furthermore, sequencing quality looks identical in both whole islet (high RIN) and 
sorted beta cell (lower RIN) populations. Furthermore, we can show that exon 
coverage is similar across the whole gene and predominates over intron 
coverage. We believe that the presence of intron sequence is a result of our 
inability to select mature messenger RNA sequences via polyadenylated tail 
enrichment techniques and not due to genomic DNA contamination because we 
perform two separate DNase steps to completely remove all unwanted DNA. We 
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have extracted sufficient amounts (> 200 ng) of total RNA, both mRNA and 
miRNA with acceptable RIN values, from alpha and beta cells from two additional 
human islet donors. This will allow us to determine the differential gene 
expression between the two cell types and confirm the miRNA findings from the 
HTG technique. Since the time from RNA extraction to sequencing results is 
about 60 days, we hope to have these results in early September.  
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CHAPTER V 
FINAL SUMMARY AND CONCLUSIONS 
Pancreatic endocrine cells are co-located into clusters called the islets of 
Langerhans that are predominantly comprised of glucagon producing alpha cells, 
insulin secreting beta cells, somatostatin generating delta cells, and other cell 
types.  The regulated release of these hormones maintains whole body glucose 
homeostasis, essential to prevent complications from diabetes (e.g. blindness, 
kidney failure, and cardiovascular disease). In type 1 diabetes, an autoimmune 
reaction destroys the beta cells and patients must monitor their blood sugar 
levels and inject insulin in order to maintain euglycemia. In type 2 diabetes, the 
beta cells fail to produce sufficient insulin to overcome the individual’s decreased 
insulin sensitivity. Most studies to date have focused on whole islets, which are 
very heterogeneous.  Recent focus has shifted to studying the individual islet cell 
subsets (i.e. alpha, beta, delta, PP, and other cell types). Unlike immunological 
cells, surface molecule reagents do not yet exist to specifically distinguish beta 
from alpha cells, although recent studies have made progress in this 
direction25,26,49. Furthermore, the composition of the pancreas as a 95% exocrine 
organ produces a hostile environment rich in RNase molecules that degrade 
RNA quality, a factor that has confounded complete gene expression studies.  
We have worked to adapt flow cytometry and intracellular hormone staining to 
sort pure populations of individual human pancreatic islet cell subsets. We have 
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characterized the relative expression and proportion of insulin producing beta 
cells to glucagon producing alpha cells in human donors based upon age, BMI, 
and gender. Although the current sample size is small, these types of studies, 
which are a byproduct of our sorting technique, could provide clues to how 
pancreatic islet composition contributes to the interruption of whole body glucose 
homeostasis. In addition, we have used a quantitative nuclease protection assay, 
modified from previous mouse studies, to measure gene expression in low 
quality RNA27. Finally, we have worked to improve RNA quality. By streamlining 
our sorting and RNA extraction protocols, we have improved RNA quality and 
performed next generation sequencing analysis to begin to define the 
transcriptome of human islet cell subtypes, most notably the human beta cell.  
As described at the end of Chapter IV, additional RNA samples from human (and 
nonhuman primate) whole islets and sorted alpha and beta cells have been sent 
out for next generation sequencing. These samples will be very important to 
assess our approach’s accuracy and reproducibility. We will soon have 
sequenced the transcriptome of three distinct whole islet, alpha cell, and beta cell 
populations that were isolated from three different donors. Analysis of the 
nonhuman primate rhesus macaque (Macaca mulatta) will provide gene 
sequence currently unavailable from the draft genome of this species49. By 
carrying out these experiments, we will fill a gap in the availability of sequence 
data for this species, which will help make it a more amenable model system to 
molecular biological and genetic analysis. Finally, the NHP samples that we have 
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sent for sequencing include a whole islet NHP preparation that was not fixed, 
stained, or sorted (unprocessed) versus a whole islet NHP preparation that was 
fixed, stained, and mock sorted through the flow cytometer as a heterogeneous 
mixture of cells (processed).  This experiment will provide us with the ability to 
determine if sample processing changes the nature and quality of the sequences 
that can be detected in the sample.  
The following plan outlines how we will assess the NGS technology as a useful 
tool for analyzing transcriptomes from fixed and sorted cells. The outlined 
experiments specifically focus on pancreatic islets and their associated, sorted 
cell subtypes Our validation and findings, however may be directly applied to 
other samples previously stored as formalin fixed, paraffin embedded tissue. 
These FFPE samples comprise a vast resource for patient or subject samples 
related to a specific disease or clinical trial. Through our studies, we aim to 
interrogate, develop, and establish a NGS protocol for these types of samples 
that have traditionally been precluded from downstream quantitative gene 
expression analysis due to poor RNA quantity and quality50. As advances are 
made in improving the quantitative capabilities, turn around time, and expense of 
NGS, we hope that our analysis will permit analysis of these RNA samples. 
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VALIDATING OUR APPROACH FOR ISLET CELL SUBSET TRANSCRIPTOME SEQUENCING 
1.) Compare sequencing results between unprocessed and processed 
“whole islets” that were derived from the same donor.  
• Compare total number and identity of genes expressed in the 
two samples. 
• Compare the gene rank lists for each sample. 
• Plot expression levels for all genes against each other and 
calculate correlation coefficient. 
• Compare internal ratios of select genes between the two 
samples. 
The comparisons will allow us to determine if processing the islets by fixing, 
permeabilizing, staining, and sorting qualitatively and quantitatively alters 
observed gene expression characteristics. We hypothesize that the 
processed and unprocessed samples will display no qualitative differences, 
however, as described below, quantitative biases could arise for the most 
highly expressed genes. 
Given the stated limitations introduced by double stranded nuclease 
treatment in precluding quantitative gene expression analysis, we could also 
compare sequencing results from unprocessed and processed “whole islets” 
using traditional sequencing preparation steps: 
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• Enrich each sample for polyadenylated species using 
immobilized oligo (dT) – average 50-fold enrichment of mRNA51 
or 
• Deplete ribosomal RNA contaminants by using immobilized 
sequences designed to selectively hybridize with ribosomal 
RNA. By immobilizing rRNA species, desired mRNA (regardless 
of polyadenylated tail status) can be enriched and purified, 
increasing the number of mRNA specific reads in NGS 
analysis52.  
• Perform sequencing as described with DSN treatment step. 
This study would allow us to determine if traditional mRNA enrichment 
methods would eliminate the need to perform DSN and provide us with better 
data for gene quantification. In this scenario, we would compare mapped 
gene transcripts across all three samples (both processed and unprocessed) 
to determine the relative affects of DSN, polyA enrichment, ribosomal RNA 
depletion on an RNA sample of high integrity and then see if these results 
were reproduced in the processed sample. We would look to see if transcripts 
were biased toward either the 3’ end of a gene or toward genes comprised of 
longer transcripts in one treatment or the other. We would also determine how 
many transcripts were mapped in each sample, compare the intronic versus 
exonic composition of each read, and identify any gross differences brought 
about in one treatment versus the others. If ribosomal rRNA depletion or 
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enrichment based upon poly adenylation status increased mRNA composition 
of the sample without introducing any of the biases discussed above, a much 
larger percentage of the NGS reads we generate would be specific to 
expressed genes. Eliminating the need to perform DSN (thus increasing the 
number of mRNA-specific reads) coupled with barcoding each sample with a 
unique tag would allow us to combine samples for sequencing within the 
same lane – together, these steps would markedly reduce the cost and 
reagents needed to perform each experiment27,53. 
APPLYING OUR APPROACH TO BETTER UNDERSTAND PANCREATIC ISLET BIOLOGY 
2.) Compare sequencing results among all three samples of each 
population. 
• We have noted that the ratio of alpha cells to beta cells varies from 
donor to donor.  
• Which genes are consistently expressed in alpha cells or beta cells 
and how do relative expression levels differ? 
This analysis will allow us to determine this technique’s reproducibility by 
measuring the percentage of similar genes detected across multiple donors. 
 
3.) Compare sequencing results between alpha and beta cell 
populations. 
• Plot expression levels for all genes against each other and 
calculate the correlation coefficient.  
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• Perform gene set enrichment analysis (GSEA) for each population. 
• Compare results to published literature in order to assess relative 
quantities of known genes. 
These analyses will allow us to compare the differential gene expression 
between alpha and beta cells. Since alpha and beta cells are both secretory 
endocrine cells we wish to observe the similarities and differences between 
their transcriptomes.  
MEASURING GENE EXPRESSION CHANGES IN DIFFERENT CELL SUBSETS  
 
4.) Quantitating and validating results using gene expression assays 
• Retest expression and relative expression ratios using qNPA or 
Nanostring technology – compare to NGS results. 
• Assess utility of qPCR to confirm these results as related to starting 
mRNA quality. 
• Measure gene expression changes among donors with specific 
characteristics (gender, BMI, diagnosed as type 2 diabetics), islets 
that have been treated with small molecules (GLP-1 analogues, 
sulfonylureas, high glucose), or in model systems where diet, 
exercise, age, and lifestyle can be controlled (NHP or human islets 
transplanted into appropriate mouse models).   
Double stranded nuclease treatment currently compromises quantitation via 
next generation sequencing. Currently, each next generation sequencing 
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reaction is fairly expensive and the turn around time for results (both 
generating the sequencing files, assembling the transcriptome, and then 
analyzing the results for specific genes of interest (with appropriate data 
quality assessment, result normalization across donors, and elimination of 
biases)) can be quite extensive. While the technology continues to develop 
and advances are made in the turn around time and quantifying ability of 
NGS, we will benefit from developing and modifying existing tools to validate 
our NGS results and obtain quantitative data. Since our end goal is to 
establish techniques to quantitate gene expression changes among specific 
genes, we can use the NGS results that have been generated using double 
stranded nuclease treatment as a guide. This will allow us to design 
Nanostring (limit 800 candidate genes) or qNPA (limit 47 candidate genes) 
assays to quickly and reliably assess gene expression changes in a more 
cost effective manner that allows us to determine the effect of double standed 
nuclease treatment27,53. By using GSEA algorithms from sequencing results 
on sorted islet cell subtypes, we can choose a wide spectrum of genes that 
are abundantly expressed in each cell type. By measuring how the 
expression levels of these genes change in response to environmental stimuli 
hypothesized to increase beta cell mass, we can begin to identify the 
regulatory processes that control beta cell growth, development, maturation, 
redifferentiation, dedifferentiation, or death.  
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By establishing a reliable next generation sequencing platform, in 
conjunction with focused gene expression analysis, we will be able to 
study the dynamic nature of the beta cell transcriptome. This framework will 
allow us to measure differential gene expression between islet cell subtypes, 
among different developmental or disease states, or in response to 
environmental stimuli that regulate beta cell proliferative capacity and function. 
The data form specific islet cell populations will enable us to develop specific 
hypotheses regarding which genes, regulators, and pathways control glucose 
homeostasis. Improving our understanding of how individual islet cell subsets 
develop, grow, mature, and become susceptible to negative external stimuli, will 
elucidate the physiology and pathophysiology of islets, specifically the beta cell.  
We will apply this technique to the NHP model system where more control can 
be exerted over islet donor age, diet, environment, quality of life, and pre-
analysis metabolic phenotype. With scheduled islet isolations, we can minimize 
any gene expression changes associated with dysfunction, apoptosis, and 
necrosis induced by cold ischemia. By continuing to perform targeted human 
studies (e.g. control versus type 2 diabetics) and applying these to the model 
system, we will investigate how the transcriptome of beta cells changes under 
various conditions and identify pathways that dictate beta cell survival. Long 
term, this information may be applied to studies involving stem cell differentiation, 
islet transplantation, and bariatric surgery to understand which changes that 
occur in the beta cell may result in a positive and potentially therapeutic outcome. 
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